急性淋巴细胞白血病治疗市场 - 增长、趋势、COVID-19 影响和预测(2022 - 2027 年)

急性淋巴细胞白血病治疗市场按细胞类型、治疗类型(化疗、靶向治疗、放射治疗、干细胞移植)和地理划分

市场快照

CAGR
Study Period: 2018 - 2026
Base Year: 2021
Fastest Growing Market: Asia Pacific
Largest Market: North America
CAGR: 5.2 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

市场概况

导致该市场增长的主要因素之一包括全球急性淋巴细胞白血病 (ALL) 发病率的上升。每年记录的新病例数约为每 100,000 名男性和女性中的 1.7 例。美国癌症研究所估计,2019 年将有大约 5,930 例新的 ALL 病例,即男性 3,280 例,女性 2,650 例。此外,据估计,到 2020 年,亚太和南美洲国家的 ALL 病例数可能在每 100,000 人 0.4 至 2 人之间。

病例数量的增加主要是由于采用了西方生活方式,包括饮食变化和久坐不动的生活方式。此外,在全球范围内,预计在预测期内流行率将增加,这将是该市场增长的主要因素。

报告范围

根据报告的范围,急性淋巴细胞白血病 (ALL),也称为淋巴细胞白血病,是最常见的癌症类型之一,它通过淋巴结、脊髓、肝脏、脾脏和中枢神经系统在体内传播,等等。B 细胞 ALL、T 细胞 ALL 和费城染色体阳性 ALL (Ph+ ALL) 是三种最常见的原发性 ALL。B细胞ALL是最常见的类型。Ph+ ALL 患者的治疗涉及针对基因产物的精准药物。

By Type of Cell
B-cell ALL
T-cell ALL
Philadelphia Chromosome: Positive (Ph+) and Negative (Ph-) ALL
By Type of Therapy
Chemotherapy
Hyper - CVAD Regimen
CALGB 8811 Regimen
Linker Regimen
Nucleoside Inhibitors
Other Types of Therapies
Targeted Therapy
Radiation Therapy
Stem Cell Transplantation
Geography
North America
United States
Canada
Mexico
Europe
Germany
United Kingdom
France
Italy
Spain
Rest of Europe
Asia-Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East & Africa
GCC
South Africa
Rest of Middle East & Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

主要市场趋势

化疗有望主导治疗类型

美国癌症协会表示,化疗是急性淋巴细胞白血病(ALL)患者的主要治疗方法,分为缓解期、巩固期和维持期三个阶段。化疗使用细胞毒性药物来破坏癌细胞。

安吖啶 (NordMedica)、环磷酰胺 (Baxter) 和阿糖胞苷 (Pfizer) 是用于 ALL 化疗的一些药物。Baxter International 和 Pfizer 等全球制药公司正在提供这些药物。根据白血病和淋巴瘤协会 2019 年的报告,ALL 是儿童、青少年和 20 岁以下年轻人中最常见的癌症,占该年龄组所有癌症病例的 19.8%。因此,由于 ALL 的高患病率,尤其是在儿童中,化疗市场也有望得到提振。

Graph.png

北美将在预测期内主导市场

由于遗传因素、环境因素和辐射,该地区的这种疾病病例数量不断增加,预计北美将主导这一市场。此外,有利的政府政策、完善的医疗保健基础设施以及跨国公司的存在使该地区在这个市场上占据主导地位。 

由于多种因素,例如未满足的临床需求高、患者群体庞大以及新兴国家对早期诊断的认识不断提高,预计亚太地区在预测期内的复合年增长率也将很高。

Geo.png

竞争格局

急性淋巴细胞白血病市场竞争适度,由大公司和中型公司组成。由于大部分制药公司对肿瘤的关注度不断提高,预计近期内很少有新的小型公司也将进入该市场。

主要玩家

  1. Pfizer Inc.

  2. Bristol-Myers Squibb Company

  3. Novartis AG

  4. SymBio Pharmaceuticals Limited

  5. Genmab AS

leukemia therapeutics market

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Rise in the Incidences of Acute Lymphoblastic Leukemia

      2. 4.2.2 Increasing Initiatives Taken by the Government and Private Organizations

    3. 4.3 Market Restraints

      1. 4.3.1 Stringent Regulatory Pathways

      2. 4.3.2 High Cost Asscoiated with the Treatment

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Type of Cell

      1. 5.1.1 B-cell ALL

      2. 5.1.2 T-cell ALL

      3. 5.1.3 Philadelphia Chromosome: Positive (Ph+) and Negative (Ph-) ALL

    2. 5.2 By Type of Therapy

      1. 5.2.1 Chemotherapy

        1. 5.2.1.1 Hyper - CVAD Regimen

        2. 5.2.1.2 CALGB 8811 Regimen

        3. 5.2.1.3 Linker Regimen

        4. 5.2.1.4 Nucleoside Inhibitors

        5. 5.2.1.5 Other Types of Therapies

      2. 5.2.2 Targeted Therapy

      3. 5.2.3 Radiation Therapy

      4. 5.2.4 Stem Cell Transplantation

    3. 5.3 Geography

      1. 5.3.1 North America

        1. 5.3.1.1 United States

        2. 5.3.1.2 Canada

        3. 5.3.1.3 Mexico

      2. 5.3.2 Europe

        1. 5.3.2.1 Germany

        2. 5.3.2.2 United Kingdom

        3. 5.3.2.3 France

        4. 5.3.2.4 Italy

        5. 5.3.2.5 Spain

        6. 5.3.2.6 Rest of Europe

      3. 5.3.3 Asia-Pacific

        1. 5.3.3.1 China

        2. 5.3.3.2 Japan

        3. 5.3.3.3 India

        4. 5.3.3.4 Australia

        5. 5.3.3.5 South Korea

        6. 5.3.3.6 Rest of Asia-Pacific

      4. 5.3.4 Middle East & Africa

        1. 5.3.4.1 GCC

        2. 5.3.4.2 South Africa

        3. 5.3.4.3 Rest of Middle East & Africa

      5. 5.3.5 South America

        1. 5.3.5.1 Brazil

        2. 5.3.5.2 Argentina

        3. 5.3.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 Bristol Myer Squibb Company

      2. 6.1.2 Celegene Corporation

      3. 6.1.3 Eisai Co Ltd

      4. 6.1.4 Erytech Pharma

      5. 6.1.5 F. Hoffmann-La Roche Ltd

      6. 6.1.6 Genmab A/S

      7. 6.1.7 GlaxoSmithKline PLC

      8. 6.1.8 Novartis AG

      9. 6.1.9 Pfizer Inc.

      10. 6.1.10 Sanofi SA

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape Covers - Business Overview, Financials, Products and Strategies, and Recent Developments
You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Acute Lymphoblastic Leukemia Therapeutics Market market is studied from 2018 - 2026.

The Acute Lymphoblastic Leukemia Therapeutics Market is growing at a CAGR of 5.2% over the next 5 years.

Asia Pacific is growing at the highest CAGR over 2021- 2026.

North America holds highest share in 2021.

Pfizer Inc., Bristol-Myers Squibb Company, Novartis AG, SymBio Pharmaceuticals Limited, Genmab AS are the major companies operating in Acute Lymphoblastic Leukemia Therapeutics Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!